Delivery Order SPE2DB22D1017-SPE2DB25FYPPZ
- Not listed
- The Defense Logistics Agency awarded a $12,553.34 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 tablets. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $6,642.00 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitive award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages) with a firm fixed price ceiling value of $11,979.29. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside delivery order. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $15,063.99 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This competitively awarded, firm fixed-price contract was executed on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside transaction, indicating the contract was open to all qualified...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $1,664.74. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive delivery order without set-aside designation. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a ceiling value of $9,217.95. This firm fixed-price delivery order represents a non-competitive set-aside and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $4,134.12. This is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $17,527.44 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a firm fixed price structure. The order, issued on August 22, 2025, requires completion by August 25, 2025, and represents a competitive award with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPPZDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $11,924.12 on August 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical federal medical vendor supplying the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with a comprehensive range of pharmaceutical products and medical supplies. The company's extensive portfolio of federal contracts demonstrates its capability to meet diverse military and veteran healthcare requirements across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 8/29/25 |